AbbVie crashes due to disappointing drug tests, Bristol-Myers wins

AbbVie (ABBV) shares are sliding after the schizophrenia drug failed to meet goals in its mid-stage trial. Shares of Bristol-Myers Squibb (BMY), a competitor that makes a similar drug, have surged. Market Domination hosts Julie Hyman and Josh Lipton explain what investors need to know.

For more expert insights and analysis on the latest market activity, check out Market Domination here.

This post was written by Naomi Buchanan.